Alvotech SA, a global biotech company, has reported its financial results for the first quarter of 2025, showcasing a substantial increase in revenues. Total revenues climbed to $132.8 million, a significant 260% rise from the $36.9 million reported in the same period last year. Product revenues reached $109.9 million, marking a remarkable 786% increase compared to $12.4 million in the previous year's first quarter. The company also reported a net profit of $109.7 million for the three months ended March 31, 2025, a notable turnaround from the net loss of $218.7 million in the same period of the previous year. This resulted in earnings per share of $0.39, a stark contrast to the loss of $0.89 per share reported for the same period in 2024. Alvotech's Adjusted EBITDA for the first quarter of 2025 was positive at $20.5 million, compared to a negative $38.4 million in 2023. The company has increased its full-year guidance, projecting top-line revenue between $600 and $700 million and adjusted EBITDA in the range of $200 to $280 million, following the acquisition of rights to a biosimilar to Cimzia. In a business update, Alvotech highlighted its strong momentum in generating positive cash flows from operating activities and maintaining healthy product margins. The company expects to be free cash-flow positive in 2025 and self-funded moving forward, driven by new product launches and enhanced manufacturing efficiencies.